The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors.
Abstract Details
Therapeutic landscape for NAFLD in 2020
Neuschwander-Tetri BA1. Gastroenterology. 2020 Feb 12. pii: S0016-5085(20)30222-5. doi: 10.1053/j.gastro.2020.01.051. [Epub ahead of print]
Author information
1 Division of Gastroenterology and Hepatology, Saint Louis University, 3635 Vista Ave. St. Louis MO 63110. Electronic address: Brent.Tetri@health.slu.edu.
Abstract
Lifestyle modifications focused on healthy eating and regular exercise are the primary recommendations for patients with NASH. However, for multiple societal, psychological, physical, genetic, and epigenetic reasons, the ability of people to adopt and sustain such changes is challenging and typically not successful. To end the epidemic of NASHand prevent its complications including cirrhosis and hepatocellular carcinoma, pharmacological interventions are now being evaluated in clinical trials. Treatments include drugs targeting energy intake, energy disposal, lipotoxic liver injury, and the resulting inflammation and fibrogenesis that lead to cirrhosis. It is likely that patients develop the phenotype of NASH by multiple mechanisms and thus the optimal treatments of NASH will likely evolve to personalized therapy once we understand the mechanistic underpinnings of NASH in each patient. Reviewed here is the treatment landscape in this rapidly evolving field with an emphasis on drugs in Phase 2 and Phase 3 trials